secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001193125-24-145434
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial
--------------------------------------------------------------------------------

- Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.
- No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.
- Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.
- CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/0001193125-24-145434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/d823505d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-145434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer